Warhound raises $200M to engineer enhanced military working dogs

Warhound, a stealth startup founded by Colossal Biosciences CEO Ben Lamm and Anduril co-founder Palmer Luckey, has emerged with $200 million in funding to develop working dogs for military, law enforcement, and emergency response roles. The round, reportedly backed by investors including In-Q-Tel, Sequoia, and 8VC, values the company at a disclosed figure, according to TechCrunch. Warhound aims to address what it describes as a critical shortage of service dogs in the U.S. by creating dogs optimized for demanding missions, using gene-editing technology and hardware enhancements.

The company’s pitch centers on a persistent issue: a significant portion of working dogs used by the U.S. military are sourced from abroad, and many fail to meet service requirements due to genetic vulnerabilities. Warhound has suggested it could use cloning and gene editing to remove these weaknesses while enhancing traits like speed, agility, and sensory capabilities. The company has indicated that the first dogs developed through this process could be born in the near future, with potential deployment in the coming years.

Anduril’s involvement extends beyond funding. The defense tech company is expected to supply hardware and software, including protective gear with embedded sensors and tools to improve coordination between dogs and handlers. Palmer Luckey, who does not hold equity in Warhound, has described the enhancements as focused on safety and performance improvements without fundamentally altering the animals’ biology. The company has reportedly briefed government agencies about its plans, though details on regulatory pathways remain unclear.

Warhound’s approach appears to draw on Colossal’s broader efforts in gene editing, which have included projects like de-extinction. The startup is said to be collaborating with another entity under Colossal’s umbrella to handle the development process, citing experience in replicating animal traits. While pricing hasn’t been finalized, Warhound has suggested it may target buyers like the Department of Defense, police forces, and first responders. The company has also stated it will work with the American Humane Society to certify its training programs and support retired dogs.

The $200 million round reflects growing investor interest in technologies that bridge biotech and defense. Colossal’s pivot toward military working dogs suggests a strategic bet on the scalability of its gene-editing platform. Yet the project raises questions about the ethical and operational risks of deploying bioengineered animals in high-stakes environments. Unlike traditional working dogs, Warhound’s proposed creations would be bred for specific traits, which could introduce unforeseen challenges in behavior or health. The reliance on cloning may also pose biological risks, as cloned animals have historically faced complications.

For the defense sector, Warhound’s model could offer a more predictable pipeline of service dogs, potentially reducing reliance on foreign suppliers. However, the success of the venture hinges on whether governments will embrace genetically modified animals for critical roles—a precedent that doesn’t yet exist. Meanwhile, Anduril’s involvement signals a broader trend of defense contractors expanding into biotech, blending hardware, software, and living systems. As Warhound moves forward, observers will be watching for signs of regulatory pushback, field performance, and whether the company can deliver on its vision of enhanced working dogs.

Sources: techcrunch.com